Fibrosis: Oncodesign and TiumBio sign collaboration agreement for R&D of drug candidates
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix® drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates. This initial phase of the collaboration will be funded by TiumBio.
[Congress] [EN] Pharmabiotics Online, 28-29 April 2021
Home . Resources . [Congress] [EN] Pharmabiotics Online, 28-29 April 2021
Organised by the Pharmabiotic Research Institute, Pharmabiotics is an event dedicated to medicinal microbiotic products. This event brings together online all actors involved in the international human microbiome community.
Oncodesign BU Service will be present at Pharmabiotics !
Oncodesign BU Service is an innovation-based solutions and expertise provider in Drug Discovery in Oncology, Immuno-oncology and Inflammatory Diseases.
Discover SOLO- Microbiome: this offer enables to assist you in microbiome therapeutic project and strategy
This offering encloses multiple innovative hit-finding/screening capabilities, medicinal chemistry, computational chemistry, in vitro biology, ADME / DMPK, in vivo pharmacology, pharmaco-imaging/theranostic and safety assessment all applied in one-stop shop to drug discovery programs in oncology, immuno-oncology, auto-immune/ inflammatory diseases.
Oncodesign can be your partner:
to study the relationship between imbalances in microbiota and the disease of interest,
to define the role of microbiota in precision diagnosis and personalized treatment,
to develop/evaluate therapeutics derived from microbiota.
Discover Oncodesign models for pathologies related to microbiota disorders and all assays/readouts that allow us to evaluate in vitro and in vivo the impact of bacteria or derived products on cancer and inflammatory diseases and the immune responses in such context.